CA2982169A1 - Protein biomarker panels for detecting colorectal cancer and advanced adenoma - Google Patents

Protein biomarker panels for detecting colorectal cancer and advanced adenoma Download PDF

Info

Publication number
CA2982169A1
CA2982169A1 CA2982169A CA2982169A CA2982169A1 CA 2982169 A1 CA2982169 A1 CA 2982169A1 CA 2982169 A CA2982169 A CA 2982169A CA 2982169 A CA2982169 A CA 2982169A CA 2982169 A1 CA2982169 A1 CA 2982169A1
Authority
CA
Canada
Prior art keywords
catd
sepr
cea
proteins
psgl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2982169A
Other languages
English (en)
French (fr)
Inventor
John Blume
Jeffrey Jones
Ryan BENZ
Athit KAO
Lisa CRONER
Roslyn DILLON
Jia YOU
Bruce Wilcox
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Applied Proteomics Inc
Original Assignee
Applied Proteomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Proteomics Inc filed Critical Applied Proteomics Inc
Publication of CA2982169A1 publication Critical patent/CA2982169A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/60—ICT specially adapted for the handling or processing of medical references relating to pathologies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
    • G01N2333/70564—Selectins, e.g. CD62
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/99—Isomerases (5.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
CA2982169A 2015-04-10 2016-04-08 Protein biomarker panels for detecting colorectal cancer and advanced adenoma Abandoned CA2982169A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201562146158P 2015-04-10 2015-04-10
US62/146,158 2015-04-10
US201562160560P 2015-05-12 2015-05-12
US62/160,560 2015-05-12
US201562165846P 2015-05-22 2015-05-22
US62/165,846 2015-05-22
US201562196889P 2015-07-24 2015-07-24
US62/196,889 2015-07-24
US201562239771P 2015-10-09 2015-10-09
US62/239,771 2015-10-09
PCT/US2016/026773 WO2016164815A1 (en) 2015-04-10 2016-04-08 Protein biomarker panels for detecting colorectal cancer and advanced adenoma

Publications (1)

Publication Number Publication Date
CA2982169A1 true CA2982169A1 (en) 2016-10-13

Family

ID=55795201

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2982169A Abandoned CA2982169A1 (en) 2015-04-10 2016-04-08 Protein biomarker panels for detecting colorectal cancer and advanced adenoma

Country Status (7)

Country Link
US (3) US9689874B2 (https=)
EP (1) EP3281016A1 (https=)
JP (1) JP2018517892A (https=)
CA (1) CA2982169A1 (https=)
GB (1) GB2545361B (https=)
HK (1) HK1255533A1 (https=)
WO (1) WO2016164815A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9141756B1 (en) 2010-07-20 2015-09-22 University Of Southern California Multi-scale complex systems transdisciplinary analysis of response to therapy
KR101937531B1 (ko) * 2016-09-28 2019-01-10 국립암센터 대장암 진단 장치와 대장암 진단 정보 제공 방법
US20180100858A1 (en) * 2016-10-07 2018-04-12 Applied Proteomics, Inc. Protein biomarker panels for detecting colorectal cancer and advanced adenoma
CN116474108A (zh) 2016-12-14 2023-07-25 普渡研究基金会 成纤维细胞活化蛋白(fap)-靶向成像和治疗
US11062792B2 (en) 2017-07-18 2021-07-13 Analytics For Life Inc. Discovering genomes to use in machine learning techniques
US11139048B2 (en) 2017-07-18 2021-10-05 Analytics For Life Inc. Discovering novel features to use in machine learning techniques, such as machine learning techniques for diagnosing medical conditions
WO2019113239A1 (en) * 2017-12-05 2019-06-13 Discerndx, Inc. Robust panels of colorectal cancer biomarkers
WO2019193982A1 (ja) * 2018-04-04 2019-10-10 富士フイルム株式会社 医療文書作成支援装置、医療文書作成支援方法、及び医療文書作成支援プログラム
CN112970067A (zh) * 2018-06-30 2021-06-15 20/20基因系统股份有限公司 癌症分类器模型、机器学习系统和使用方法
US20200011871A1 (en) * 2018-07-05 2020-01-09 Edp Biotech Corporation Kits and methods for detecting markers
US11011276B2 (en) * 2018-07-09 2021-05-18 Chang Gung Memorial Hospital, Linkou Method for establishing computer-aided data interpretation model for immune diseases by immunomarkers and visualization
WO2021064610A1 (en) * 2019-10-01 2021-04-08 Ac Immune Sa Micro-radiobinding assays for ligand screening
US20210349017A1 (en) * 2020-05-08 2021-11-11 Caci, Inc. - Federal Systems and methods for detection of biological agents using infrared spectroscopy
US20240127444A1 (en) * 2021-02-16 2024-04-18 Verily Life Sciences Llc Systems and methods for biomarker detection in digitized pathology samples
US20250266162A1 (en) * 2021-05-13 2025-08-21 Arizona Board Of Regents On Behalf Of The University Of Arizona Method of targeted multi-panel approach and tiered a.i. use for differential diagnosis and prognosis
WO2024208824A1 (en) * 2023-04-03 2024-10-10 Oncodiag Methods for the diagnosis and surveillance of cancer
CN118983105A (zh) * 2024-06-24 2024-11-19 浙江省肿瘤医院 一种用于高级别浆液性卵巢癌晚期患者无复发生存的预测模型

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444879A (en) 1981-01-29 1984-04-24 Science Research Center, Inc. Immunoassay with article having support film and immunological counterpart of analyte
US4517289A (en) 1982-08-18 1985-05-14 Brigham And Women's Hospital Monoclonal antibodies for human tissue cross-matching
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4921789A (en) 1988-04-20 1990-05-01 New England Deaconess Hospital Corporation Marker for colorectal carcinoma and methods of detecting the same
US5344760A (en) 1991-06-03 1994-09-06 Ciba Corning Diagnostics Corp. Method of cancer detection
US5786158A (en) 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US5790761A (en) 1992-12-11 1998-08-04 Heseltine; Gary L. Method and apparatus for the diagnosis of colorectal cancer
AU6350894A (en) 1993-03-05 1994-09-26 Clifford W. Schweinfest Colon mucosa gene having down-regulated expression in colon adenomas and adenocarcinomas
US7229770B1 (en) 1998-10-01 2007-06-12 The Regents Of The University Of California YKL-40 as a marker and prognostic indicator for cancers
DK85193D0 (da) 1993-07-16 1993-07-16 Cancerforskningsfondet Af 1989 Suppression of inhibitors
US6316208B1 (en) 1994-01-07 2001-11-13 Memorial Sloan-Kettering Cancer Center Methods for determining isolated p27 protein levels and uses thereof
CA2228970A1 (en) 1995-08-18 1997-02-27 Donald W. Landry Detection of organic compounds through regulation of antibody-catalyzed reactions
US5800347A (en) 1995-11-03 1998-09-01 The General Hospital Corporation ROC method for early detection of disease
NO954667D0 (no) 1995-11-17 1995-11-17 Dagfinn Oegreid Fremgangsmåte til deteksjon av Ki-ras mutasjoner
US5983211A (en) 1996-01-24 1999-11-09 Heseltine; Gary L. Method and apparatus for the diagnosis of colorectal cancer
US6242212B1 (en) 1996-02-09 2001-06-05 Thomas Jefferson University Fragile histidine triad (FHIT) nucleic acids and methods of producing FHIT proteins
GB9810040D0 (en) 1998-05-11 1998-07-08 Univ Nottingham Blood borne tumour markers
US6303372B1 (en) 1998-06-12 2001-10-16 Chiron Corporation cDNA molecule encoding human CIF130
GB9827228D0 (en) 1998-12-10 1999-02-03 Univ Nottingham Cancer detection method and reagents
WO2000070096A2 (en) 1999-01-10 2000-11-23 Exact Laboratories, Inc. Methods of detecting colorectal disease by conduction an assay to detect a mutation in a bat-26 locus
US7153700B1 (en) 1999-03-26 2006-12-26 Dana-Farber Cancer Institute, Inc. Methods and compositions for diagnosing and predicting the behavior of cancer
AU771309B2 (en) 1999-04-09 2004-03-18 Rigshospitalet Tissue inhibitor of matrix metalloproteinases type-1 (TIMP-1) as a cancer marker
US20010041365A1 (en) 2000-01-10 2001-11-15 Michael Laposata Methods for monitoring alcohol consumption
US6322986B1 (en) 2000-01-18 2001-11-27 Albany Medical College Method for colorectal cancer prognosis and treatment selection
US7301016B2 (en) 2000-03-07 2007-11-27 Millennium Pharmaceuticals, Inc. Human transferase family members and uses thereof
US7577683B2 (en) 2000-06-08 2009-08-18 Ingenuity Systems, Inc. Methods for the construction and maintenance of a knowledge representation system
US6531283B1 (en) 2000-06-20 2003-03-11 Molecular Staging, Inc. Protein expression profiling
DE60142356D1 (de) 2000-07-18 2010-07-22 Millennium Pharm Inc 18480 humane proteinkinasemoleküle und ihre verwendungen
US6706506B2 (en) 2000-07-24 2004-03-16 Cornell Research Foundation, Inc. Detection of epithelial cell cancers and precancerous conditions
WO2002077233A2 (en) 2000-11-08 2002-10-03 Millennium Pharmaceuticals, Inc. 38650, 28472, 5495, 65507, 81588 and 14354 METHODS AND COMPOSITIONS OF HUMAN PROTEINS AND USES THEREOF
US7312086B2 (en) 2000-12-07 2007-12-25 Bristol-Myers Squibb Company Methods of diagnosing colon adenocarcinoma using the human g-protein coupled receptor hgprbmy23
US8043807B2 (en) 2001-03-23 2011-10-25 Yeda Research And Development Co. Ltd. Methods and kits for determining a risk to develop cancer, for evaluating an effectiveness and dosage of cancer therapy and for correlating between an activity of a DNA repair enzyme and a cancer
JP2005512510A (ja) 2001-05-16 2005-05-12 ノバルティス アクチエンゲゼルシャフト 予後および治療標的として乳癌で発現される遺伝子
US7031846B2 (en) 2001-08-16 2006-04-18 Affymetrix, Inc. Method, system, and computer software for the presentation and storage of analysis results
US8029764B2 (en) 2001-09-07 2011-10-04 The Johns Hopkins University Methods for detection of colorectal cancer
US20040018973A1 (en) 2002-01-25 2004-01-29 University Of Pittsburgh Nuclear matrix protein alterations associated with colon cancer and colon metastasis to the liver, and uses thereof
US20030186248A1 (en) 2002-03-29 2003-10-02 Erlander Mark G. Interpreting cytological specimens via molecular histological signatures
EP1367395A1 (de) 2002-05-02 2003-12-03 B.R.A.H.M.S Aktiengesellschaft Diagnose von Neoplasmen mit Hilfe von anti-Gangliosid-Antikörpern
WO2003097872A2 (en) 2002-05-21 2003-11-27 Mtm Laboratories Ag G - protein coupled receptor marker molecules associated with colorectal lesions
US20050153382A1 (en) 2002-06-06 2005-07-14 Chengdu Kuachang Science And Technology Co., Ltd. Biochip kit comprising biochip based on antigen-antibody reactions, and its usage
US7425700B2 (en) 2003-05-22 2008-09-16 Stults John T Systems and methods for discovery and analysis of markers
US7526387B2 (en) 2003-07-10 2009-04-28 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
DE102004037860A1 (de) 2004-08-04 2006-03-16 Friedrich-Alexander-Universität Erlangen-Nürnberg Turmormarker zur Diagnose von Karzinomen und/oder davon abstammender Metastasen
PT1761779E (pt) 2004-08-13 2008-02-01 Indivumed Gmbh Utilização de transtirretina como um biomarcador de adenoma colorrectal; método de detecção e sistema de teste
US20060105419A1 (en) 2004-08-16 2006-05-18 Biosite, Inc. Use of a glutathione peroxidase 1 as a marker in cardiovascular conditions
WO2006047483A2 (en) 2004-10-22 2006-05-04 Redpath Integrated Pathology, Inc. Dynamic genomic deletion expansion and formulation of molecular marker panels for integrated molecular pathology diagnosis and characterization of tissue, cellular fluid, and pure fluid specimens
WO2006047787A2 (en) 2004-10-27 2006-05-04 Exact Sciences Corporation Method for monitoring disease progression or recurrence
WO2006094149A2 (en) 2005-03-01 2006-09-08 Exact Sciences Corporation Methods and compositions for detecting adenoma
US9075062B2 (en) 2005-03-22 2015-07-07 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Identification of biomarkers by serum protein profiling
US20090150315A1 (en) 2005-07-29 2009-06-11 Siemens Healthcare Diagnostics Inc. Neoplastic Disease-Related Methods, Kits, Systems and Databases
KR20080049821A (ko) 2005-09-12 2008-06-04 페노미넘 디스커버리스 인코포레이티드 비타민 ｅ-관련 대사산물의 측정에 의한 결장암 및난소암의 진단방법
US20080255764A1 (en) 2005-09-12 2008-10-16 Phenomenome Discoveries Inc. Methods for the Diagnosis of Colorectal Cancer and Ovarian Cancer by the Measurement of Vitamin E-Related Metabolites
US7892758B2 (en) 2005-09-27 2011-02-22 University Of Saskatchewan Use of N-myristoyltransferase on non-tumor tissue for cancer diagnosis
WO2007141595A2 (en) 2005-11-10 2007-12-13 Aurelium Biopharma Inc. Method of diagnosing breast cancer using protein markers
GB0524190D0 (en) 2005-11-28 2006-01-04 Helse Stavanger Hf Method
ES2277785B1 (es) 2005-12-21 2008-06-16 Oryzon Genomics, S.A. Metodo de analisis de expresion diferencial en cancer colorectal.
US20090035801A1 (en) 2005-12-27 2009-02-05 Power3 Medical Products, Inc. Twelve (12) protein biomarkers for diagnosis and early detection of breast cancer
NZ593226A (en) 2006-01-11 2012-10-26 Genomic Health Inc Gene expression markers (efnb2) for colorectal cancer prognosis
WO2007090125A2 (en) 2006-01-30 2007-08-09 Introgen Therapeutics, Inc. Prognostic factors for anti-hyperproliferative disease gene therapy
WO2007127002A2 (en) 2006-03-31 2007-11-08 Cell Signaling Technology, Inc. Protein markers of responsiveness to type iii receptor tyrosine kinase inhibitors
US7736624B2 (en) 2006-06-19 2010-06-15 Univ Vanderbilt Methods and compositions for diagnostic and therapeutic targeting of COX-2
US7811778B2 (en) 2006-09-06 2010-10-12 Vanderbilt University Methods of screening for gastrointestinal cancer
ES2543015T3 (es) 2006-12-08 2015-08-13 The Johns Hopkins University Estrategia de quimioprevención del cáncer basada en la pérdida de la impronta de IGF2
EP2111550B1 (en) 2007-01-26 2011-11-30 University Of Louisville Research Foundation, Inc. Methods of detecting autoantibodies for diagnosing and characterizing disorders
WO2008116178A2 (en) 2007-03-21 2008-09-25 Vanderbilt University Systems and methods for diagnosis and prognosis of colorectal cancer
AU2008300338A1 (en) 2007-06-04 2009-03-26 Diagnoplex Biomarker combinations for colorectal cancer
WO2009015299A1 (en) 2007-07-26 2009-01-29 California Pacific Medical Center Method to predict or diagnose a gastrointestinal disorder or disease
DE102007034993A1 (de) 2007-07-26 2009-01-29 Hanna Diehl Lösliches Cadherin 17 für die Diagnose und Risikostratifizierung von Darmtumor oder Darmkrebs
EP2195658A2 (en) 2007-09-28 2010-06-16 Royal College of Surgeons in Ireland A method of assessing colorectal cancer status in an individual
JP5227418B2 (ja) 2007-11-20 2013-07-03 エフ．ホフマン−ラ ロシュ アーゲー マーカー組み合わせカルプロテクチンおよびヘモグロビン／ハプトグロビン複合体の使用による便試料からの結腸直腸癌の評価方法
KR101058753B1 (ko) 2007-11-22 2011-08-24 한국생명공학연구원 대장암 마커로서의 ｅｓｍ－１ 유전자 및 이를 이용한대장암의 진단 및 치료에의 용도
MX2010004671A (es) 2007-12-10 2010-05-27 Hoffmann La Roche Seprasa como marcador para cancer.
ES2527649T3 (es) * 2007-12-10 2015-01-28 F. Hoffmann-La Roche Ag Panel de marcadores para el cáncer colorrectal
WO2009099649A1 (en) 2008-02-08 2009-08-13 Poniard Pharmaceuticals, Inc. Use of picoplatin and bevacizumab to treat colorectal cancer
WO2009101620A1 (en) 2008-02-11 2009-08-20 Hadasit Medical Research Services & Development Limited Colon cancer associated transcript 1 (ccat1) as a cancer marker
WO2009107170A1 (ja) 2008-02-29 2009-09-03 学校法人日本大学 抗ｃｒｐ抗体及びその利用
WO2009115920A1 (en) 2008-03-18 2009-09-24 Epigenomics Ag A method for optimizing and validating an assay for determining the presence or absence of a medical condition
CA2718918A1 (en) 2008-03-25 2009-11-26 Schering Corporation Methods for treating or preventing colorectal cancer
US8921074B2 (en) 2008-04-10 2014-12-30 Genenews, Inc. Method and apparatus for determining a probability of colorectal cancer in a subject
CA2724433A1 (en) 2008-05-14 2009-11-19 Eth Zuerich Method for biomarker and drug-target discovery for prostate cancer diagnosis and treatment as well as biomarker assays determined therewith
EP2796878A1 (en) 2008-05-23 2014-10-29 Biocartis NV New biomarkers for diagnosis, prediction and/or prognosis of sepsis and uses thereof
WO2010009368A2 (en) 2008-07-18 2010-01-21 Oragenics, Inc. Compositions for the detection and treatment of colorectal cancer
EP2169077A1 (en) 2008-09-19 2010-03-31 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Methods and compositions for diagnosing an adenocarcinoma
US20100204299A1 (en) 2009-02-11 2010-08-12 Daniel Regnier C-cbl and antagonists thereof for the treatment and diagnosis of cancer
WO2010096154A2 (en) * 2009-02-20 2010-08-26 Onconome, Inc. Compositions and methods for diagnosis and prognosis of colorectal cancer
CN102326081B (zh) 2009-02-24 2014-11-19 霍夫曼-拉罗奇有限公司 s-ErbB-3作为癌症标志物的应用
CA2777800C (en) 2009-10-15 2019-11-12 Crescendo Bioscience Biomarkers and methods for measuring and monitoring inflammatory disease activity
US7736861B1 (en) 2009-10-19 2010-06-15 Aveo Pharmaceuticals, Inc. Tivozanib response prediction
EP2501845A4 (en) * 2009-11-20 2013-04-24 Univ Louisville Res Found KREBSBIOMARKER
US20110236916A1 (en) 2010-03-26 2011-09-29 Mayo Foundation For Medical Education And Research Methods and materials for detecting colorectal neoplasm
US10119959B2 (en) 2010-06-25 2018-11-06 The Board Of Trustees Of The Leland Stanford Junior University Method of assaying an individual for immune impairment
GB201012590D0 (en) 2010-07-27 2010-09-08 Queen Mary & Westfield College Methods for diagnosing cancer
US8389684B2 (en) 2010-09-13 2013-03-05 Tsinghua University Tumor biomarker
EP2668503B1 (en) 2011-01-28 2015-06-24 F.Hoffmann-La Roche Ag Combinatorial biomarkers for clinical applications in lung cancer patient management
WO2012115885A1 (en) 2011-02-22 2012-08-30 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers
EP2744919A4 (en) 2011-08-19 2015-04-08 Myriad Genetics Inc GENE SIGNATURES FOR PROGNOSIS OF LUNG CANCER AND SELECTION OF THERAPY
WO2013152989A2 (en) 2012-04-10 2013-10-17 Eth Zurich Biomarker assay and uses thereof for diagnosis, therapy selection, and prognosis of cancer
EP3671215B1 (en) * 2012-04-26 2023-03-29 Stichting VUmc Biomarkers
WO2014085826A2 (en) 2012-11-30 2014-06-05 Applied Proteomics, Inc. Method for evaluation of presence of or risk of colon tumors

Also Published As

Publication number Publication date
WO2016164815A1 (en) 2016-10-13
GB201703773D0 (en) 2017-04-26
HK1255533A1 (zh) 2019-08-16
US9689874B2 (en) 2017-06-27
US20170370937A1 (en) 2017-12-28
JP2018517892A (ja) 2018-07-05
US20160299144A1 (en) 2016-10-13
US20190257835A1 (en) 2019-08-22
GB2545361B (en) 2018-01-24
EP3281016A1 (en) 2018-02-14
GB2545361A (en) 2017-06-14

Similar Documents

Publication Publication Date Title
US9689874B2 (en) Protein biomarker panels for detecting colorectal cancer and advanced adenoma
Bhawal et al. Challenges and opportunities in clinical applications of blood-based proteomics in cancer
Hussein et al. A review of the most promising biomarkers for early diagnosis and prognosis prediction of tongue squamous cell carcinoma
Njoku et al. Proteomic biomarkers for the detection of endometrial cancer
JP6956762B2 (ja) 心血管系のリスクイベントの予測及びその使用
US20180100858A1 (en) Protein biomarker panels for detecting colorectal cancer and advanced adenoma
HK1248316A1 (en) Methods of assessing colorectal health of an individual
Cima et al. Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer
US20170176441A1 (en) Protein biomarker profiles for detecting colorectal tumors
KR102111624B1 (ko) 심혈관 위험 사건 예측 및 그것의 용도
CN104969071B (zh) 用于评估结肠肿瘤的存在或风险的方法
Toss et al. Ovarian cancer: can proteomics give new insights for therapy and diagnosis?
CN121726086A (zh) 多组学评估
Huang et al. Inflammation markers have important value in predicting relapse in patients with papillary thyroid carcinoma: a long-term follow-up retrospective study
Neagu et al. In search of ideal solutions for cancer diagnosis: From conventional methods to protein biomarkers in liquid biopsy
Mukherjee et al. Comprehending the proteomic landscape of ovarian cancer: a road to the discovery of disease biomarkers
Ransohoff et al. Assessment of serum proteomics to detect large colon adenomas
KR20240004546A (ko) 결장직장암에 대한 바이오마커
Njoku Novel biomarkers for endometrial cancer diagnosis and prognosis
Lin et al. Application of proximity ligation assays to identify potential plasma biomarkers in oral cavity cancer patients: A case control study
Malik et al. Understanding the role of biomarkers in cancer

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220629